Comparative Analysis of HPV16 Variants in the Untranslated Regulatory Region, L1, and E6 Genes Among Vaccinated and Unvaccinated Young Women: Assessing Vaccine Efficacy and Viral Diversity

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2024 Sep 28

PMID 39339857

Authors

Kahren van Eer

Tsira Dzebisasjvili

Renske D M Steenbergen

Audrey J King

Affiliations

Soon will be listed here.

Abstract

HPV16 is occasionally detected in vaccinated women who received the bivalent HPV16/18 vaccine, usually at low viral loads. This study explored potential differences in HPV16 variants between vaccinated and unvaccinated women. HPV16-postive viral loads were detected in 1.9% (17/875) and 13% (162/760) of vaccinated and unvaccinated women, respectively, showcasing the vaccine's high efficacy. The L1, E6, and URR regions of HPV16 were sequenced from genital swabs from 16 vaccinated and 25 unvaccinated women in the HAVANA (HPV Among Vaccinated And Non-vaccinated Adolescents) study. The majority of HPV16 variants from vaccinated and unvaccinated women clustered similarly with sub-lineages A1 and A2. Additionally, a separate cluster within lineage A was found, with the variants sharing the L1-located SNP A753G (synonymous) and the URR-located SNP T340C, which did not occur in the other variants. Furthermore, four variants from vaccinated women had relatively long branches, but were not characterized by specific SNPs. The frequency of G712A in the URR was the only SNP observed to be marginally higher among vaccinated women than unvaccinated women. Non-synonymous SNPs T266A in the FG-loop of L1 and L83V in E6 were common among variants from vaccinated and unvaccinated women, but present in similar frequencies. In conclusion, the detection of HPV16 in vaccinated (and unvaccinated) women seemed to be the result of random circulation within this study population.

Citing Articles

Human Papillomavirus-Related Cancer Vaccine Strategies.

Cai X, Xu L Vaccines (Basel). 2024; 12(11).

PMID: 39591193 PMC: 11598756. DOI: 10.3390/vaccines12111291.

References

Yang B, Zhang L, Zhang A, Zhou A, Yuan J, Wang Y . Variant sublineages of human papillomavirus type 16 predispose women to persistent infection characterized by a sequence analysis of the E6, L1, and LCR regions. Int J Clin Exp Pathol. 2020; 12(1):337-343. PMC: 6943999. View

de Sanjose S, Serrano B, Tous S, Alejo M, Lloveras B, Quiros B . Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58. JNCI Cancer Spectr. 2019; 2(4):pky045. PMC: 6649711. DOI: 10.1093/jncics/pky045. View

Mirabello L, Yeager M, Yu K, Clifford G, Xiao Y, Zhu B . HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis. Cell. 2017; 170(6):1164-1174.e6. PMC: 5674785. DOI: 10.1016/j.cell.2017.08.001. View

Lehtinen M, Paavonen J, Wheeler C, Jaisamrarn U, Garland S, Castellsague X . Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2011; 13(1):89-99. DOI: 10.1016/S1470-2045(11)70286-8. View

Harper D . Impact of vaccination with Cervarix (trade mark) on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age. Gynecol Oncol. 2008; 110(3 Suppl 1):S11-7. DOI: 10.1016/j.ygyno.2008.06.029. View

Benschop K, Broberg E, Hodcroft E, Schmitz D, Albert J, Baicus A . Molecular Epidemiology and Evolutionary Trajectory of Emerging Echovirus 30, Europe. Emerg Infect Dis. 2021; 27(6):1616-1626. PMC: 8153861. DOI: 10.3201/eid2706.203096. View

Kavanagh K, Pollock K, Cuschieri K, Palmer T, Cameron R, Watt C . Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis. 2017; 17(12):1293-1302. DOI: 10.1016/S1473-3099(17)30468-1. View

Naud P, Roteli-Martins C, de Carvalho N, Teixeira J, de Borba P, Sanchez N . Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother. 2014; 10(8):2147-62. PMC: 4896780. DOI: 10.4161/hv.29532. View

Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B . Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 2022; 11(2):e197-e206. PMC: 9848409. DOI: 10.1016/S2214-109X(22)00501-0. View

10.

Clifford G, Tenet V, Georges D, Alemany L, Pavon M, Chen Z . Human papillomavirus 16 sub-lineage dispersal and cervical cancer risk worldwide: Whole viral genome sequences from 7116 HPV16-positive women. Papillomavirus Res. 2019; 7:67-74. PMC: 6374642. DOI: 10.1016/j.pvr.2019.02.001. View

11.

Burk R, Harari A, Chen Z . Human papillomavirus genome variants. Virology. 2013; 445(1-2):232-43. PMC: 3979972. DOI: 10.1016/j.virol.2013.07.018. View

12.

Walboomers J, Jacobs M, Manos M, Bosch F, Kummer J, Shah K . Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189(1):12-9. DOI: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F. View

13.

Mirabello L, Clarke M, Nelson C, Dean M, Wentzensen N, Yeager M . The Intersection of HPV Epidemiology, Genomics and Mechanistic Studies of HPV-Mediated Carcinogenesis. Viruses. 2018; 10(2). PMC: 5850387. DOI: 10.3390/v10020080. View

14.

Olcese V, Chen Y, Schlegel R, Yuan H . Characterization of HPV16 L1 loop domains in the formation of a type-specific, conformational epitope. BMC Microbiol. 2004; 4:29. PMC: 499545. DOI: 10.1186/1471-2180-4-29. View

15.

Debernardi A, Valot B, Almarcha J, Guenat D, Hocquet D, Algros M . Longitudinal follow-up of HPV16 sequence after cervical infection: Low intrahost variation and no correlation with clinical evolution. J Med Virol. 2022; 94(11):5512-5518. DOI: 10.1002/jmv.27978. View

16.

Oumeslakht L, Ababou M, Badaoui B, Qmichou Z . Worldwide genetic variations in high-risk human papillomaviruses capsid L1 gene and their impact on vaccine efficiency. Gene. 2021; 782:145533. DOI: 10.1016/j.gene.2021.145533. View

17.

van Eer K, Middeldorp M, Dzebisasjvili T, Lamkaraf N, de Melker H, Steenbergen R . Effects of 2 and 3 Vaccinations With the Bivalent Human Papillomavirus (HPV) Vaccine on the Prevalence and Load of HPV in Clearing and Persistent Infections in Young Women. J Infect Dis. 2023; 228(8):1012-1022. DOI: 10.1093/infdis/jiad080. View

18.

Pastrana D, Vass W, Lowy D, Schiller J . NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16. Virology. 2001; 279(1):361-9. DOI: 10.1006/viro.2000.0702. View

19.

van der Weele P, van Logchem E, Wolffs P, van den Broek I, Feltkamp M, de Melker H . Correlation between viral load, multiplicity of infection, and persistence of HPV16 and HPV18 infection in a Dutch cohort of young women. J Clin Virol. 2016; 83:6-11. DOI: 10.1016/j.jcv.2016.07.020. View

20.

Schwarz T, Galaj A, Spaczynski M, Wysocki J, Kaufmann A, Poncelet S . Ten-year immune persistence and safety of the HPV-16/18 AS04-adjuvanted vaccine in females vaccinated at 15-55 years of age. Cancer Med. 2017; 6(11):2723-2731. PMC: 5673947. DOI: 10.1002/cam4.1155. View